

1.1 moves to amend H.F. No. 100, the third engrossment, as follows:

1.2 Page 59, after line 18, insert:

1.3 "Subd. 6. **Disclosures.** Before completing a sale to a customer, a cannabis retailer must
1.4 provide the customer with information about the possible risks and side effects of using
1.5 cannabis flower, cannabinoid products, and hemp-derived consumer products. The office
1.6 shall identify the risks and side effects that must be disclosed. Disclosure must be consistent
1.7 with information from the Division of Medical Cannabis provided by a health care
1.8 practitioner to a patient before the patient is enrolled in the registry program. The office
1.9 shall make the list of required disclosures available to the public and shall immediately
1.10 notify all licensed cannabis retailers of a change in the required disclosures."

1.11 Renumber the subdivisions in sequence